482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

• Judy Wang,
• Filip Janku,
• Manish Sharma,
• Johanna Bendell,
• Amit Mahipal,
• George Dranitsaris,
• Aleksandra Filipovic,
• Zev Wainber,
• Joseph Bolen,
• Eric Elenko,
• Christopher Korth

Affiliations

Judy Wang

1 Vascular Surgery, Northern Hospital, Epping, Victoria, Australia

Filip Janku

Department of Investigational Cancer Therapeutics, University of Texas at MD Anderson Cancer Center, Houston, Texas, USA

Manish Sharma

4 Department of Emergency Medicine, NewYork-Presbyterian Queens, Flushing, New York, USA

Johanna Bendell

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee, USA

Amit Mahipal

Aff5 grid.170693.a000000012353285XMoffitt Cancer Center Tampa FL USA

George Dranitsaris

consultant pharmacist

Aleksandra Filipovic

1Puretech Health, Boston, MA, USA

Zev Wainber

2UCLA School of Medicine, Los Angeles, CA, USA

Joseph Bolen

1Puretech Health, Boston, MA, USA

Eric Elenko

1Puretech Health, Boston, MA, USA

Christopher Korth

1Puretech Health, Boston, MA, USA